India rejects patent on Pfizer's arthritis drug

MUMBAI (Reuters) – India has again denied Pfizer Inc a patent on its rheumatoid arthritis drug tofacitinib, the latest setback for a multinational drugmaker seeking to enforce its intellectual property rights in the country.